This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
NIHR HSRIC. Nivolumab (Opdivo) for metastatic or unresectable urothelial bladder cancer – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016
Urothelial bladder cancer starts to develop in the bladder lining. In some cases the tumour spreads into the surrounding muscles or other parts of the body, which means that it cannot be cured by surgery. Most bladder cancers occur in people aged over 60 years. Almost one third of people diagnosed with bladder cancer will be diagnosed with disease that has spread outside of the bladder.
Nivolumab is a new antibody drug for the treatment of bladder cancer and is delivered straight into the bloodstream via a drip. It may stimulate the immune system to attack cancer cells. A study underway at the moment is aiming to find out how well nivolumab works in people whose first treatment has failed and whose disease has spread.
If nivolumab is licenced for use in the UK, it could be a new treatment option for patients with bladder cancer that may improve survival when current treatments have stopped working.
Subject indexing assigned by CRD
Antibodies, Monoclonal; Carcinoma, Transitional Cell; Humans; Urinary Bladder Neoplasms; Urologic Neoplasms
Country of organisation
An English language summary is available.
Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: email@example.com
Date abstract record published